Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
STTK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
6 hours ago
globenewswire.com
6 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
16 hours ago
globenewswire.com
17 hours ago
Forecast
2026-Revenue
-139%2026-EPS
88%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
2.00(100.00%)
Number of analyst
1
Last analyst upgrade/downgrade
Needham
downgradePrevious: Buy
2024-10-02
Now: Hold
Citigroup
downgradePrevious: Buy
2024-10-01
Now: Neutral
H.C. Wainwright
downgradePrevious: Buy
2024-10-01
Now: Neutral
H.C. Wainwright
downgradePrevious: Buy
2024-10-01
Now: Negative
Quote Panel
Key Metrics
Relative Strength
STTK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01Ā ( 1.00%)
Relative Strenght
10
Volume Buzz
-81%
Earning Acce
Yes
Dist 52w H.
75%Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.65
vsĀ -0.58
Q4.23
N/A
-0.41
vsĀ -0.60
Q1.24
N/A
-0.37
vsĀ -0.49
Q2.24
N/A
-0.42
vsĀ -0.50
Q3.24
N/A
-0.33
vsĀ -0.65
Q4.24
N/A
-0.37
vsĀ -0.41
Q1.25
N/A
-0.27
vsĀ -0.37
Q2.25
N/A
-0.24
vsĀ -0.42
Q3.25
N/A
-0.15
vsĀ -0.33
Q4.25
N/A
-0.16
vsĀ -0.37
Sales Growth
YoY
Current
Estimates
Q1.23
NA
57KĀ vsĀ NA
Q2.23
+300%
200KĀ vsĀ 50K
Q3.23
+224%
686KĀ vsĀ 212K
Q4.23
+83%
714KĀ vsĀ 390K
Q1.24
+1856%
1.1MĀ vsĀ 57K
Q2.24
+705%
1.6MĀ vsĀ 200K
Q3.24
+337%
3MĀ vsĀ 686K
Q4.24
+4761%
34.7MĀ vsĀ 714K
Q1.25
-100%
NAĀ vsĀ 1.1M
Q2.25
-100%
NAĀ vsĀ 1.6M
Return on Equity
QoQ
Q1.23
-13%
-0.13
vsĀ -0.14
Q2.23
-15%
-0.15
vsĀ -0.13
Q3.23
-24%
-0.24
vsĀ -0.15
Q4.23
-12%
-0.12
vsĀ -0.24
Q1.24
-14%
-0.14
vsĀ -0.12
Q2.24
-19%
-0.19
vsĀ -0.14
Q3.24
-17%
-0.17
vsĀ -0.19
Q4.24
-23%
-0.23
vsĀ -0.17
Q1.25
-20%
-0.20
vsĀ -0.23
Q2.25
-22%
-0.22
vsĀ -0.20
Institutionnal Ownership
QoQ
Q4.22
48
48
vsĀ 62
-23%
Q1.23
49
49
vsĀ 48
2%
Q2.23
41
41
vsĀ 49
-16%
Q3.23
41
41
vsĀ 41
NA
Q4.23
64
64
vsĀ 41
56%
Q1.24
75
75
vsĀ 64
17%
Q2.24
77
77
vsĀ 75
3%
Q3.24
79
79
vsĀ 77
3%
Q4.24
74
74
vsĀ 79
-6%
Q1.25
75
75
vsĀ 74
1%